This phase I study was designed as a monocentric, open‐label one arm trial with the primary objective of determining a safe and tolerable dose for the combination treatment with E and S in patients with advanced solid malignancies (escalation part) and NSCLC patients harboring KRAS mutation (expansion part). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.